MorphoSys (MOR) PT Set at €64.00 by HSBC
MorphoSys (ETR:MOR) has been assigned a €64.00 ($76.19) target price by equities researchers at HSBC in a research report issued to clients and investors on Friday. The brokerage currently has a “sell” rating on the stock. HSBC’s target price would indicate a potential downside of 26.48% from the stock’s previous close.
MOR has been the subject of a number of other research reports. Goldman Sachs Group set a €72.00 ($85.71) target price on MorphoSys and gave the company a “neutral” rating in a report on Wednesday, November 8th. Berenberg Bank set a €85.00 ($101.19) target price on MorphoSys and gave the company a “buy” rating in a report on Wednesday, November 1st. Deutsche Bank set a €90.00 ($107.14) target price on MorphoSys and gave the company a “buy” rating in a report on Wednesday, November 8th. Independent Research set a €93.00 ($110.71) price target on MorphoSys and gave the company a “buy” rating in a report on Friday, December 1st. Finally, JPMorgan Chase & Co. set a €85.00 ($101.19) price target on MorphoSys and gave the company a “buy” rating in a report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of €81.56 ($97.09).
MorphoSys (ETR:MOR) opened at €87.05 ($103.63) on Friday. MorphoSys has a fifty-two week low of €47.10 ($56.07) and a fifty-two week high of €87.10 ($103.69). The company has a market capitalization of $2,560.00 and a P/E ratio of -29.51.
MorphoSys Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.